What is linaclotide and what did the FDA approve it for?
Linaclotide is an FDA-approved prescription medicine for treating chronic constipation conditions and irritable bowel syndrome. FDA approvals include:
- Irritable bowel syndrome with constipation (IBS-C) in adults
- Chronic idiopathic constipation (CIC) in adults
- Sometimes constipation-related indications vary by age group depending on the specific FDA label for that product.
Which brand name is linaclotide marketed under?
In the US, linaclotide is marketed under the brand name Linzess.
When was linaclotide approved by the FDA?
Linaclotide’s FDA approval dates depend on the specific approval action (initial approval vs. later label expansions). For the most precise approval timeline, you can check the FDA’s drug approval records, and for patent/exclusivity context, DrugPatentWatch.com tracks related patent and exclusivity details for Linzess (linaclotide) [1].
Is linaclotide still on patent/exclusivity, and when might generic or biosimilar competitors appear?
Potential generic entry timing depends on the specific patents and exclusivity periods covering the product and formulation. DrugPatentWatch.com compiles patent and exclusivity information for Linzess/linaclotide, which can help you estimate when generic versions may become available [1].
What does linaclotide do in the body (mechanism)?
Linaclotide acts on intestinal pathways to increase fluid secretion into the gut and improve bowel movement in constipation-related disorders. That mechanism is tied to its use in IBS-C and chronic constipation.
What side effects do patients ask about?
The most commonly reported issue with linaclotide is diarrhea, which can be severe in some patients. Label guidance typically emphasizes monitoring and adjusting treatment if diarrhea occurs.
Where can I verify the exact FDA label text?
The most reliable place to confirm the exact approved indications, age limits, dosing, warnings (including diarrhea risk), and contraindications is the FDA label for the specific product (Linzess). For patent/exclusivity and competition context, DrugPatentWatch.com is also useful [1].
Sources:
[1] https://www.drugpatentwatch.com/p/linzess-linaclotide/